Chr. Hansen and Novozymes write history as Denmark’s largest merger, scaling up production
date:Dec 20, 2022
5, the expected organic revenue growth compound annual growth rate is 6% to 8%.

While it combines our two companies, Novozymes is paying a premium to Chr. Hansens shareholders and, thereby, Novozymes is the surviving entity, asserts Lund.

Based on Novozymes closing share price of its B-shares as of December 9, 2022, the Merger Consideration is to be received by Chr. Hansens eligible free float shareholders represent a premium of approximately 49% to Chr. Hansens closing price on December 9, 2

04/21 10:21